Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Loop diuretic

Bumetanide

Burinex

Dosage form
Tablet
Available strengths
1 mg, 5 mg
Drug class
Loop diuretic
Common brand
Burinex

Clinical overview. Bumetanide (Burinex) is a potent loop diuretic used to treat fluid retention caused by congestive heart failure, liver cirrhosis, or kidney disease, including nephrotic syndrome. It works quickly to increase urine output but can cause significant loss of fluid and electrolytes, so regular blood tests are recommended. Patients should watch for signs of dehydration, low potassium, or skin reactions, and never restart the drug if a severe skin reaction occurs.

Indication

Common therapeutic uses

  • Bumetanide is used to treat fluid retention (edema) associated with congestive heart failure.
  • Bumetanide is used to treat fluid retention associated with cirrhosis of the liver.
  • Bumetanide is used to treat fluid retention associated with kidney disease, including nephrotic syndrome.

Pregnancy

Risk assessment and monitoring considerations

  • Bumetanide may cause harmful effects during pregnancy to the fetus or newborn and should not be used during pregnancy unless the mother's clinical condition, such as heart failure, requires treatment and the potential benefit outweighs the potential risk to the fetus.

Breastfeeding

Infant exposure considerations

  • Bumetanide passes into breast milk and should not be used during breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • No data are available in patients over 65 years of age, so Health Canada has not authorized a specific geriatric indication; older adults may be at higher risk of profound water and electrolyte loss and vascular complications from excessive diuresis.

Pediatrics

Use in children and adolescents

  • No data are available in children, so Health Canada has not authorized bumetanide for pediatric use.

Dosage & Administration

Practical dosing and administration

  • The usual total daily dose is 0.5 mg to 2.0 mg, often given as a single dose.
  • If the response to an initial 1 mg dose is inadequate, a second or third dose may be given at 4- to 5-hour intervals, up to a maximum recommended daily dose of 10 mg.
  • An intermittent dosing schedule, such as dosing on alternate days or for 3 to 4 days with 1 to 2 rest days in between, is recommended as the safest and most effective way to control ongoing edema.
  • In patients with liver failure, the dose should be kept to a minimum, increased very cautiously, and generally not exceed 5 mg daily; a maintenance dose as low as 0.5 mg daily should be considered.
  • If a dose is missed, it should be taken as soon as remembered, unless the next dose is due within 4 hours, in which case the missed dose should be skipped; doses should never be doubled.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose can cause signs of electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, and drowsiness.
  • Confusion, gastrointestinal upset, restlessness, muscle pain, cramps, and seizures may also occur from electrolyte imbalance.
  • Excess fluid and electrolyte loss can lead to dehydration and reduced blood volume.
  • Severe volume depletion may progress to circulatory collapse, with a risk of blood clots (vascular thrombosis and embolism).
  • Treatment involves stopping bumetanide and replacing lost fluids and electrolytes.

Common side effects

Frequently reported tolerability concerns

  • Nausea may occur.
  • Abdominal pain may occur.
  • Peripheral swelling (edema) may occur.
  • Electrolyte imbalances, including low potassium, low sodium, low chloride, or high potassium, may occur.
  • Muscle cramps may occur.
  • Dizziness, including orthostatic light-headedness, may occur.
  • Difficulty urinating (micturition disorder) may occur.
  • Shortness of breath (dyspnea) may occur.
  • Headache may occur.
  • Vomiting may occur.
  • Diarrhea may occur.
  • Constipation may occur.
  • Dry mouth may occur.
  • Upset stomach may occur.
  • Chest discomfort may occur.
  • Weakness or malaise may occur.
  • Excessive thirst may occur.
  • Sweating may occur.
  • Impaired hearing or ear discomfort may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Toxic epidermal necrolysis and Stevens-Johnson syndrome, which can be life-threatening or fatal, have been reported with bumetanide; treatment must be stopped immediately if either is suspected and never restarted in that patient.
  • Excessive diuresis can cause profound water loss, electrolyte depletion, dehydration, reduced blood volume, and circulatory collapse, with a risk of blood clots, particularly in elderly patients.
  • Hepatic encephalopathy, including coma, may be precipitated in patients with liver cirrhosis and ascites if electrolyte balance shifts suddenly.
  • Ototoxicity (hearing damage), particularly with high doses or in patients with severe kidney impairment, may occur.
  • Kidney failure has been reported.
  • Bone marrow suppression, including pancytopenia, thrombocytopenia, leukopenia (including neutropenia), and anemia, has been reported after approval.
  • Severe cutaneous adverse reactions beyond Stevens-Johnson syndrome and toxic epidermal necrolysis, including significant rash, dermatitis, and photosensitivity, have been reported.
  • Gout may be precipitated due to increased blood uric acid levels.
  • Seizures have been reported in association with severe electrolyte disturbances.
  • Seek urgent medical attention for widespread rash or skin peeling, mouth sores, severe dizziness, muscle cramps with weakness, confusion, or a significant decrease in urination while taking bumetanide.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients on digitalis glycosides, since low potassium increases sensitivity to digitalis toxicity.
  • Use with caution in patients with hepatic cirrhosis and ascites, since sudden electrolyte shifts can trigger hepatic encephalopathy.
  • Use with caution in patients with severe kidney impairment, particularly regarding the risk of ototoxicity and reversible rises in blood urea nitrogen and creatinine.
  • Use with caution in patients with a potential obstruction of the urinary tract.
  • Use with caution in patients on low-salt diets, since rigid sodium restriction is not advisable and can worsen low sodium or low potassium levels.
  • Use with caution in patients taking proton pump inhibitors, since the combination may worsen low magnesium levels.
  • Use with caution in diabetic patients or those with latent diabetes, since bumetanide may affect glucose tolerance and periodic blood glucose monitoring is advised.
  • Use with caution in patients with known hypersensitivity to sulfonamides, since there may be a risk of cross-sensitivity to bumetanide.
  • Use with caution in patients with low blood pressure, and reduce the dose or stop treatment if it occurs.
  • Serum electrolytes, including potassium, should be monitored regularly during treatment, especially with high doses or prolonged use.
  • Bumetanide is banned in competitive sports and can be detected in routine anti-doping urine testing.
  • Advise patients that dizziness may occur, so caution is needed before driving or using machinery.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with hypersensitivity to bumetanide, other sulfonamide derivatives, or any ingredient in the formulation.
  • Contraindicated in patients with anuria (absence of urine production).
  • Contraindicated in patients with hepatic encephalopathy, including coma.
  • Contraindicated in patients with severe electrolyte depletion.
  • Contraindicated in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since the tablets contain lactose.

Drug interactions

Clinically relevant combinations

  • Digitalis glycosides: low potassium from bumetanide increases sensitivity to digitalis and the risk of toxicity, including nausea, vomiting, and arrhythmias.
  • Non-depolarizing neuromuscular blocking agents: low potassium from bumetanide increases sensitivity to these agents, so use with caution.
  • Lithium: bumetanide reduces lithium clearance, which can raise lithium blood levels; concomitant use should generally be avoided, and if necessary requires close monitoring of lithium levels and lower lithium doses.
  • Class III antiarrhythmic drugs: combined use may increase the risk of electrolyte imbalance and cardiotoxicity, including QT prolongation, torsades de pointes, or cardiac arrest.
  • Probenecid: inhibits the kidney's elimination of bumetanide, reducing its diuretic effect.
  • NSAIDs: may increase the risk of kidney toxicity when combined with bumetanide, and blood pressure and kidney function should be monitored.
  • Antihypertensive medications and other drugs causing postural hypotension, such as tricyclic antidepressants: bumetanide may increase their blood-pressure-lowering effect, risking first-dose hypotension.
  • Other potassium-depleting drugs: combined use with bumetanide increases the risk of low potassium and should generally be avoided, especially in patients with impaired kidney function.
  • Aminoglycoside antibiotics: bumetanide may increase the risk of kidney toxicity and hearing damage associated with these drugs.

Food interactions

Meal-related administration

  • Bumetanide can be taken with or without food; absorption is not significantly affected by meals.

Time of administration

Practical scheduling

  • Take once daily at a consistent time, with or without food.

Storage

Product handling

  • Store the 1 mg tablet below 30°C.
  • Store the 5 mg tablet between 15°C and 25°C.
  • Protect tablets from light by keeping the blister in its outer carton.

Patient take-away

Key counselling points for a quick closing summary

  • Bumetanide is a potent diuretic used to reduce fluid buildup from heart, liver, or kidney disease, and patients should watch for signs of dehydration, low potassium, or skin reactions such as rash or blistering, seeking prompt medical attention if these occur, since careful dosing and monitoring are essential to avoid excessive fluid and electrolyte loss.

References

Source material and product information

  1. Health Canada Product Monograph — Bumetanide

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.